Company intelligence / Profile preview

Cannovum

Berlin, Berlin, Germany

Ownership: Private
Development stage: Other

Overview

Cannovum is focused on producing and distributing high-quality, pharmaceutical-grade medical cannabis for patients in Germany and Europe, prioritizing sustainable cultivation and medical education. It was the first German pharmaceutical cannabis company listed on the public markets. Their products are used for treating chronic pain, spasticity, and other recognized cannabis-related indications, distributed primarily through pharmacies[1][3][4].

Therapeutic areas: NeurologyOther
Modalities: Plant-derived therapySmall molecule
Industry: Biotech

Partnerships

Triple Crown Ventures (strategic investor, parent)

Beyond the preview

Go deeper on Cannovum.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cannovum.

Explore the full profile